Recordati Industria Chimica e Farmaceutica Balance Sheet Health
Financial Health criteria checks 4/6
Recordati Industria Chimica e Farmaceutica has a total shareholder equity of €1.9B and total debt of €1.5B, which brings its debt-to-equity ratio to 81.6%. Its total assets and total liabilities are €4.2B and €2.3B respectively. Recordati Industria Chimica e Farmaceutica's EBIT is €698.4M making its interest coverage ratio 9.3. It has cash and short-term investments of €235.0M.
Key information
81.6%
Debt to equity ratio
€1.53b
Debt
| Interest coverage ratio | 9.3x |
| Cash | €235.02m |
| Equity | €1.88b |
| Total liabilities | €2.33b |
| Total assets | €4.20b |
Recent financial health updates
We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20
We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Recent updates
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jan 05Do Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings Warrant Your Attention?
Dec 18We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings
Nov 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60
Nov 14Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 13Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar
Oct 31Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 07We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price
Aug 01Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Financial Position Analysis
Short Term Liabilities: REC's short term assets (€1.3B) exceed its short term liabilities (€906.7M).
Long Term Liabilities: REC's short term assets (€1.3B) do not cover its long term liabilities (€1.4B).
Debt to Equity History and Analysis
Debt Level: REC's net debt to equity ratio (69.1%) is considered high.
Reducing Debt: REC's debt to equity ratio has reduced from 96% to 81.6% over the past 5 years.
Debt Coverage: REC's debt is well covered by operating cash flow (34.6%).
Interest Coverage: REC's interest payments on its debt are well covered by EBIT (9.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 01:23 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Charles Pitman-King | Barclays |
| Vincent Meunier | BNP Paribas Exane |